[{"id":"53a3393c-70b7-4bcc-a8e3-5120097c6768","acronym":"OVELIA","url":"https://clinicaltrials.gov/study/NCT04906395","created_at":"2021-05-28T13:52:36.773Z","updated_at":"2025-02-25T12:28:09.357Z","phase":"Phase 3","brief_title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","source_id_and_acronym":"NCT04906395 - OVELIA","lead_sponsor":"Tolmar Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Eligard (leuprolide acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-24"},{"id":"06f9902f-3398-49ea-bdd4-ce2518db4d3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04886531","created_at":"2021-05-14T12:52:33.790Z","updated_at":"2025-02-25T13:49:09.000Z","phase":"Phase 2","brief_title":"Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers","source_id_and_acronym":"NCT04886531","lead_sponsor":"Ruth O'Regan","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-21"},{"id":"7e70ebdc-cdaa-4580-9eb1-432961d43354","acronym":"CAMBRIA-2","url":"https://clinicaltrials.gov/study/NCT05952557","created_at":"2023-07-20T14:08:53.643Z","updated_at":"2025-02-25T14:18:07.526Z","phase":"Phase 3","brief_title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","source_id_and_acronym":"NCT05952557 - CAMBRIA-2","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 5500","initiation":"Initiation: 10/05/2023","start_date":" 10/05/2023","primary_txt":" Primary completion: 03/04/2030","primary_completion_date":" 03/04/2030","study_txt":" Completion: 05/06/2037","study_completion_date":" 05/06/2037","last_update_posted":"2025-02-18"},{"id":"e36e7d0b-dea5-4fa8-afc8-fa11a5c8624f","acronym":"ASPIRE","url":"https://clinicaltrials.gov/study/NCT03691493","created_at":"2021-01-18T18:05:38.724Z","updated_at":"2025-02-25T14:07:17.394Z","phase":"Phase 2","brief_title":"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis","source_id_and_acronym":"NCT03691493 - ASPIRE","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/08/2019","start_date":" 02/08/2019","primary_txt":" Primary completion: 10/13/2022","primary_completion_date":" 10/13/2022","study_txt":" Completion: 10/13/2022","study_completion_date":" 10/13/2022","last_update_posted":"2025-02-17"},{"id":"89c18e67-5d9f-4f4c-836e-d176238b546e","acronym":"CAMBRIA-1","url":"https://clinicaltrials.gov/study/NCT05774951","created_at":"2023-03-20T20:03:21.727Z","updated_at":"2025-02-25T15:20:21.062Z","phase":"Phase 3","brief_title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","source_id_and_acronym":"NCT05774951 - CAMBRIA-1","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 4300","initiation":"Initiation: 03/31/2023","start_date":" 03/31/2023","primary_txt":" Primary completion: 04/20/2027","primary_completion_date":" 04/20/2027","study_txt":" Completion: 05/29/2036","study_completion_date":" 05/29/2036","last_update_posted":"2025-02-11"},{"id":"60bbdfcc-c05d-4873-8c66-614ba38bb554","acronym":"TAILORx","url":"https://clinicaltrials.gov/study/NCT00310180","created_at":"2021-01-18T01:04:07.094Z","updated_at":"2025-02-25T16:43:29.841Z","phase":"Phase 3","brief_title":"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)","source_id_and_acronym":"NCT00310180 - TAILORx","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" PGR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10273","initiation":"Initiation: 04/07/2006","start_date":" 04/07/2006","primary_txt":" Primary completion: 03/02/2018","primary_completion_date":" 03/02/2018","study_txt":" Completion: 09/30/2030","study_completion_date":" 09/30/2030","last_update_posted":"2025-02-06"},{"id":"d32e8658-c9d2-4f04-9c89-06bcade2de1e","acronym":"RxPONDER","url":"https://clinicaltrials.gov/study/NCT01272037","created_at":"2021-01-18T05:08:42.199Z","updated_at":"2025-02-25T16:36:08.722Z","phase":"Phase 3","brief_title":"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer","source_id_and_acronym":"NCT01272037 - RxPONDER","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5018","initiation":"Initiation: 01/15/2011","start_date":" 01/15/2011","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2025-02-06"},{"id":"bbd54b62-457a-494d-90d2-1614ae83c172","acronym":"DESTINY-Breast08","url":"https://clinicaltrials.gov/study/NCT04556773","created_at":"2021-01-18T21:46:53.987Z","updated_at":"2025-02-25T16:45:09.442Z","phase":"Phase 1","brief_title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT04556773 - DESTINY-Breast08","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/17/2020","start_date":" 12/17/2020","primary_txt":" Primary completion: 08/16/2023","primary_completion_date":" 08/16/2023","study_txt":" Completion: 12/04/2025","study_completion_date":" 12/04/2025","last_update_posted":"2025-02-05"},{"id":"fbf3716a-0c89-444d-8fe3-c713df6342b5","acronym":"RaPhLRR","url":"https://clinicaltrials.gov/study/NCT05467891","created_at":"2022-07-21T12:57:26.496Z","updated_at":"2025-02-25T15:54:32.807Z","phase":"Phase 2","brief_title":"Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05467891 - RaPhLRR","lead_sponsor":"Oana Danciu","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2025-01-31"},{"id":"b411be81-667e-4173-a340-a9d384984b56","acronym":"EUROPA","url":"https://clinicaltrials.gov/study/NCT04134598","created_at":"2021-01-18T20:11:54.546Z","updated_at":"2025-02-25T17:30:03.177Z","phase":"Phase 3","brief_title":"ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer","source_id_and_acronym":"NCT04134598 - EUROPA","lead_sponsor":"Azienda Ospedaliero-Universitaria Careggi","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 926","initiation":"Initiation: 02/08/2021","start_date":" 02/08/2021","primary_txt":" Primary completion: 04/08/2025","primary_completion_date":" 04/08/2025","study_txt":" Completion: 04/08/2030","study_completion_date":" 04/08/2030","last_update_posted":"2025-01-30"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"be7d6188-2112-45b6-8dd9-1605ed39cec6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04294225","created_at":"2021-01-18T20:50:11.614Z","updated_at":"2025-02-25T17:36:33.824Z","phase":"Phase 2","brief_title":"Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer","source_id_and_acronym":"NCT04294225","lead_sponsor":"Mayo Clinic","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole"],"overall_status":"Completed","enrollment":" Enrollment 161","initiation":"Initiation: 04/28/2020","start_date":" 04/28/2020","primary_txt":" Primary completion: 12/12/2022","primary_completion_date":" 12/12/2022","study_txt":" Completion: 12/12/2022","study_completion_date":" 12/12/2022","last_update_posted":"2025-01-28"},{"id":"8a9f44be-fc46-4b3c-891d-8961656bffed","acronym":"KEYNOTE 287","url":"https://clinicaltrials.gov/study/NCT02779751","created_at":"2021-01-17T18:04:05.704Z","updated_at":"2025-02-25T16:04:45.290Z","phase":"Phase 1","brief_title":"A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer","source_id_and_acronym":"NCT02779751 - KEYNOTE 287","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • PD-L1 • KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["HER-2 • PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Verzenio (abemaciclib) • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 02/03/2020","primary_completion_date":" 02/03/2020","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-01-24"},{"id":"cbfdb786-2bdb-4bd6-ab84-5ea52effef85","acronym":"EMBER-4","url":"https://clinicaltrials.gov/study/NCT05514054","created_at":"2022-08-24T21:07:46.773Z","updated_at":"2025-02-25T16:18:06.124Z","phase":"Phase 3","brief_title":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","source_id_and_acronym":"NCT05514054 - EMBER-4","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Inluriyo (imlunestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 10/04/2022","start_date":" 10/04/2022","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 03/01/2032","study_completion_date":" 03/01/2032","last_update_posted":"2025-01-22"},{"id":"9bd1e9a9-d299-4cd7-9dec-ff2f9d5e954f","acronym":"PATINA","url":"https://clinicaltrials.gov/study/NCT02947685","created_at":"2021-07-13T22:54:47.342Z","updated_at":"2025-02-25T13:52:11.472Z","phase":"Phase 3","brief_title":"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer","source_id_and_acronym":"NCT02947685 - PATINA","lead_sponsor":"Alliance Foundation Trials, LLC.","biomarkers":" PIK3CA • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • PIK3CA mutation","tags":["PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Ibrance (palbociclib) • Perjeta (pertuzumab) • fulvestrant • letrozole • anastrozole • exemestane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 496","initiation":"Initiation: 06/21/2017","start_date":" 06/21/2017","primary_txt":" Primary completion: 10/15/2024","primary_completion_date":" 10/15/2024","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2025-01-13"},{"id":"25a4e8fa-1698-459b-bd19-1f109f35e7bd","acronym":"TRAK-ER","url":"https://clinicaltrials.gov/study/NCT04985266","created_at":"2021-08-02T14:53:00.458Z","updated_at":"2025-02-25T15:00:01.624Z","phase":"Phase 2","brief_title":"A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer","source_id_and_acronym":"NCT04985266 - TRAK-ER","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • tamoxifen • fulvestrant • letrozole • anastrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 1100","initiation":"Initiation: 03/30/2022","start_date":" 03/30/2022","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2024-12-05"},{"id":"4bef796b-b171-4b4a-a80a-d9b7dc98b70c","acronym":"PIKASSO-01","url":"https://clinicaltrials.gov/study/NCT05307705","created_at":"2022-04-01T20:54:05.809Z","updated_at":"2025-02-25T16:17:30.808Z","phase":"Phase 1","brief_title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","source_id_and_acronym":"NCT05307705 - PIKASSO-01","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • Inluriyo (imlunestrant) • LOXO-783"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 193","initiation":"Initiation: 05/11/2022","start_date":" 05/11/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-10-26"},{"id":"79775896-981f-4795-860c-5b8a8ca129f9","acronym":"ADEPT","url":"https://clinicaltrials.gov/study/NCT04569747","created_at":"2021-01-18T21:49:27.045Z","updated_at":"2025-02-25T12:27:45.281Z","phase":"Phase 2","brief_title":"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","source_id_and_acronym":"NCT04569747 - ADEPT","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • letrozole • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 375","initiation":"Initiation: 01/11/2021","start_date":" 01/11/2021","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2024-10-01"},{"id":"cf8bf0b5-ca6f-4f6e-a44f-54ab88c53b60","acronym":"FACILE","url":"https://clinicaltrials.gov/study/NCT03944434","created_at":"2021-01-18T19:25:17.328Z","updated_at":"2025-02-25T15:43:30.551Z","phase":"Phase 2","brief_title":"FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT03944434 - FACILE","lead_sponsor":"Fondazione Sandro Pitigliani","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • letrozole • anastrozole • triptorelin • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 12/27/2018","start_date":" 12/27/2018","primary_txt":" Primary completion: 12/27/2024","primary_completion_date":" 12/27/2024","study_txt":" Completion: 11/27/2025","study_completion_date":" 11/27/2025","last_update_posted":"2024-09-25"},{"id":"fdfde5f1-2d71-4b49-937e-9e4a41a85a52","acronym":"","url":"https://clinicaltrials.gov/study/NCT04539496","created_at":"2021-01-18T21:43:19.578Z","updated_at":"2025-02-25T17:11:32.340Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors","source_id_and_acronym":"NCT04539496","lead_sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole • anastrozole • Xuan Yue Ning (bireociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 402","initiation":"Initiation: 05/22/2018","start_date":" 05/22/2018","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-09-13"},{"id":"a896ec8e-9825-4531-a478-c93b653bba25","acronym":"","url":"https://clinicaltrials.gov/study/NCT02057133","created_at":"2021-01-17T17:28:58.622Z","updated_at":"2025-02-25T14:00:24.405Z","phase":"Phase 1","brief_title":"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread","source_id_and_acronym":"NCT02057133","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • CDK4 • CDK6","pipe":" | ","alterations":" HR positive • HER-2 negative • EGFR positive","tags":["HER-2 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • everolimus • tamoxifen • Perjeta (pertuzumab) • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • samotolisib (LY3023414) • loperamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 03/10/2014","start_date":" 03/10/2014","primary_txt":" Primary completion: 03/15/2021","primary_completion_date":" 03/15/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-08-28"},{"id":"8de4d7db-b43c-41a6-8f13-2314cfe133b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03304080","created_at":"2021-01-18T16:19:15.513Z","updated_at":"2025-02-25T13:52:24.282Z","phase":"Phase 1/2","brief_title":"Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast","source_id_and_acronym":"NCT03304080","lead_sponsor":"Icahn School of Medicine at Mount Sinai","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Ibrance (palbociclib) • Perjeta (pertuzumab) • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 12/20/2017","start_date":" 12/20/2017","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-08-01"},{"id":"08e2ca85-8428-4328-94c8-5d64e49e90df","acronym":"","url":"https://clinicaltrials.gov/study/NCT00893061","created_at":"2021-01-18T03:25:23.407Z","updated_at":"2024-07-02T16:34:25.786Z","phase":"Phase 3","brief_title":"Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer","source_id_and_acronym":"NCT00893061","lead_sponsor":"Centre Oscar Lambret","biomarkers":" ER","pipe":" | ","alterations":" PGR positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/16/2009","start_date":" 03/16/2009","primary_txt":" Primary completion: 04/04/2012","primary_completion_date":" 04/04/2012","study_txt":" Completion: 11/26/2014","study_completion_date":" 11/26/2014","last_update_posted":"2024-06-14"},{"id":"257efb56-d6a9-4885-8a27-1e1f2000a80a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04469764","created_at":"2021-01-18T21:28:46.959Z","updated_at":"2024-07-02T16:34:37.400Z","phase":"Phase 2","brief_title":"Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer","source_id_and_acronym":"NCT04469764","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" CDK4","pipe":"","alterations":" ","tags":["CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole • anastrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 10/16/2020","start_date":" 10/16/2020","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-06-07"}]